Abstract
On December 22, 2014, the FDA granted accelerated approval to nivolumab (OPDIVO; Bristol-Myers Squibb) for the treatment of patients with unresectable......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
